Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell Lymphoma - PubMed
5 hours ago
- #CAR T-cell therapy
- #Large B-cell lymphoma
- #Landmark analysis
- CAR T-cell therapy has transformed treatment for relapsed/refractory large B-cell lymphoma (LBCL), but durable remissions remain challenging.
- A retrospective multicenter study evaluated 479 LBCL patients treated with commercial CD19 CAR-T products (axi-cel, tisa-cel, liso-cel) using serial landmark analyses.
- Progression-free survival (PFS) was assessed at multiple time points (Day 28, 3, 6, 12, 18, and 24 months post-infusion) to determine relapse risk and sustained remission.
- Patients achieving complete response (CR) early had significantly improved PFS.
- Elevated pre-lymphodepletion lactate dehydrogenase (LDH) levels were independently associated with inferior PFS and overall survival (OS) at multiple landmarks.
- Cumulative relapse and non-relapse mortality (NRM) estimates supported the prognostic value of sustained CR.
- The study suggests a trend toward cure with CAR T-cell therapy, though longer follow-up is needed to confirm durable remission.